Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

EMBER-2: A Phase 1, Open-Label, Preoperative Window Study Evaluating the Biological Effects of LY3484356 in Post-menopausal Women With Stage I-III Estrogen Receptor-Positive, HER2-Negative Breast Cancer

NCT04647487 is registered in ClinicalTrials.gov with Eli Lilly and Company as lead sponsor.

NCT NCT04647487
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04647487 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
EMBER-2: A Phase 1, Open-Label, Preoperative Window Study Evaluating the Biological Effects of LY3484356 in Post-menopausal Women With Stage I-III Estrogen Receptor-Positive, HER2-Negative Breast Cancer
Lead sponsor
Eli Lilly and Company
Phase
Phase 1
Overall status
Completed
Start date
April 21, 2021
Completion date
November 11, 2022
Enrollment
87 (actual)
Sites
19

Conditions

As the registry lists them; a condition with its own page is linked.

breast cancer